- The European Commission (EC) has approved Bristol Myers Squibb & Co's BMY Opdivo (nivolumab) as adjuvant treatment of adult patients with esophageal or gastroesophageal junction (GEJ) cancer.
- The approval covers patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT).
- The EC's decision is based on results from the Phase 3 CheckMate -577 trial, which demonstrated that treatment with Opdivo following neoadjuvant CRT and complete surgical resection doubled the primary endpoint of disease-free survival, compared to placebo in the all-randomized population.
- Price Action: BMY shares closed at $68.15 on Thursday.
- Related content: Benzinga's Full FDA Calendar.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.